Form 4: Entrada Therapeutics Director Receives Stock Options

Director Kush Parmar was granted 19,000 stock options in Entrada Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Kush Parmar received a grant of 19,000 stock options for Entrada Therapeutics, Inc. (TRDA).
• The options have an exercise price of $5.97 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $5.97 exercise price.

Future Outlook

The options vest on the earlier of the one-year anniversary of the grant date (June 10, 2027) or the date of the issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector, intended to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation packages for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common practice to ensure director retention through the governance cycle.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Trading, Stock Options, Director Compensation